<code id='BB51ADEAFA'></code><style id='BB51ADEAFA'></style>
    • <acronym id='BB51ADEAFA'></acronym>
      <center id='BB51ADEAFA'><center id='BB51ADEAFA'><tfoot id='BB51ADEAFA'></tfoot></center><abbr id='BB51ADEAFA'><dir id='BB51ADEAFA'><tfoot id='BB51ADEAFA'></tfoot><noframes id='BB51ADEAFA'>

    • <optgroup id='BB51ADEAFA'><strike id='BB51ADEAFA'><sup id='BB51ADEAFA'></sup></strike><code id='BB51ADEAFA'></code></optgroup>
        1. <b id='BB51ADEAFA'><label id='BB51ADEAFA'><select id='BB51ADEAFA'><dt id='BB51ADEAFA'><span id='BB51ADEAFA'></span></dt></select></label></b><u id='BB51ADEAFA'></u>
          <i id='BB51ADEAFA'><strike id='BB51ADEAFA'><tt id='BB51ADEAFA'><pre id='BB51ADEAFA'></pre></tt></strike></i>

          focus

          focus

          author:Wikipedia    Page View:9918
          Photo illustration of a checkbook wrapped with lock and chain – hospital and investment coverage from STAT
          Alex Hogan/STAT

          Hospitals once dove headfirst into venture capital with splashy headlines and attention-grabbing numbers. Now, in an era of flattened margins and exceedingly uncertain returns, many health systems are quietly pulling back.

          NewYork-Presbyterian’s venture firm, once managing roughly $40 million in assets, was essentially dissolved, two former employees said, with leaders punting it from the system’s strategy division to innovation, then from innovation to the investment office — a spokesperson described it as being “integrated” into the broader strategy. PitchBook data show no investments after 2020.

          advertisement

          Advocate Health Enterprises, meanwhile, the venture firm of a 67-hospital system based in Charlotte, N.C., has lost at least six employees within the past year, including its president, from a staff that once included about a dozen people.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          Amylyx's ALS drug launch starts strong. It could be trouble for FDA
          Amylyx's ALS drug launch starts strong. It could be trouble for FDA

          MollyFerguson/STATBehindthestellarcommerciallaunchofAmylyxPharmaceuticals’treatmentforALSliesanuncom

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

          2:58FormerPresidentandRepublicanpresidentialcandidateDonaldTrumpreactsasheholdsacampaignrallyinErie,